Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Clinical trial NCT05918861 · RECRUITING

Trial details

NCT number: NCT05918861
Sponsor: DalCor Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Coronary Syndrome

Start date: 2023-10-03
Primary completion: 2027-08-01
Enrollment: 2000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.